Heather Lehman
Pediatric Allergy/Immunology · Buffalo, NYNPI 1801096219
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $8,294 of the $11,383 with a category attached, or 72.9%. 13 manufacturers reported payments, led by Pharming Healthcare, Inc. at 35.6% of the total. 2025 is the largest year on record at $5,997, 7.7 times the $779 reported in 2019.
Across 37 payments — averaging $307.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pharming Healthcare, Inc.$4K
- Chiesi USA, Inc.$3K
- Sanofi$2K
- Aimmune Therapeutics, Inc.$525
- GSK$267
- AstraZeneca$253
- plus $790 from 7 others
Across 38 payments — averaging $9394.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$196K
- Chiesi USA, Inc.$67K
- Kedrion S.p.a.$48K
- Leadiant Biosciences, Inc.$37K
- Takeda Pharmaceuticals U.S.A., Inc.$10K
What the payments were for
- Consulting fees$8,29473%
- Speaking & faculty fees$8257%
- Travel & lodging$2242%
- Food & beverage$2,00818%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pharming Healthcare, Inc. | 4 | $4,049 |
| Chiesi USA, Inc. | 2 | $3,125 |
| Sanofi | 12 | $2,373 |
| Aimmune Therapeutics, Inc. | 3 | $525 |
| GSK | 4 | $267 |
| AstraZeneca | 3 | $253 |
| Genentech USA, Inc. | 2 | $240 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $140 |
| Regeneron Healthcare Solutions, Inc. | 1 | $125 |
| CSL Behring | 1 | $125 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $125 |
| Grifols USA, LLC | 1 | $19 |
| Sarepta Therapeutics, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,383 in reported general payments places this provider in the 80th percentile of 51 pediatric allergy/immunology providers in New York.
See all pediatric allergy/immunology providers in New York →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 14 | $124,041 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Cuvitru | $140 | $124,04114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 51 pediatric allergy/immunology providers in New York.
Other pediatric allergy/immunology in Buffalo
- Jeffrey RockoffBuffalo$20K
- Viveka de GuerraBuffalo$237
- Sujatha RameshBuffalo$121
- Michael MarcusBrooklyn$1.3M
- Jordan OrangeNew York$203K
- Vincent BonaguraGreat Neck$138K
- Anna Nowak-WegrzynNew York$74K
- Ramsay FuleihanNew York$68K
- Wayne ShrefflerNew York$52K
- Julie WangNew York$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.